Barbura Nicoleta, Porosnicu Tamara Mirela, Papurica Marius, Badea Mihail-Alexandru, Bedreag Ovidiu, Bratosin Felix, Lazureanu Voichita Elena
Doctoral School, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Anaesthesia and Intensive Care Research Center, Faculty of Medicine, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Biomedicines. 2025 Jul 26;13(8):1829. doi: 10.3390/biomedicines13081829.
Severe sepsis complicated by refractory shock is associated with high mortality. Adding continuous hemofiltration to venovenous extracorporeal membrane oxygenation (ECMO) may accelerate clearance of inflammatory mediators and improve haemodynamic stability, but evidence remains limited. We analysed 44 consecutive septic-shock patients treated with combined ECMO-hemofiltration (ECMO group) and compared them with 92 septic-shock patients managed without ECMO or renal replacement therapy (non-ECMO group). This retrospective single-centre study reviewed adults admitted between January 2018 and March 2025. Demographic, haemodynamic, laboratory and outcome data were extracted from electronic records. Primary outcome was 28-day mortality; secondary outcomes included intensive-care-unit (ICU) length-of-stay, vasopressor-free days, and change in Sequential Organ Failure Assessment (SOFA) score at 72 h. Baseline age (49.2 ± 15.3 vs. 52.6 ± 16.1 years; = 0.28) and APACHE II (27.8 ± 5.7 vs. 26.9 ± 6.0; = 0.41) were comparable. At 24 h, mean arterial pressure rose from 52.3 ± 7.4 mmHg to 67.8 ± 9.1 mmHg in the ECMO group (mean change [∆] + 15.5 mmHg, < 0.001). Controls exhibited a modest 4.9 mmHg rise that did not reach statistical significance ( = 0.07). Inflammatory markers decreased more sharply with ECMO (IL-6 ∆ -778 pg mL vs. -248 pg mL, < 0.001). SOFA fell by 3.6 ± 2.2 points with ECMO versus 1.6 ± 2.4 in controls ( = 0.01). Twenty-eight-day mortality did not differ (40.9% vs. 48.9%, = 0.43), but ICU stay was longer with ECMO (median 12.5 vs. 9.3 days, = 0.002). ΔIL-6 correlated with ΔSOFA (ρ = 0.46, = 0.004). ECMO-assisted hemofiltration improved early haemodynamics and organ-failure scores and accelerated cytokine clearance, although crude mortality remained unchanged. Larger prospective trials are warranted to clarify survival benefit and optimal patient selection.
严重脓毒症合并难治性休克与高死亡率相关。在静脉-静脉体外膜肺氧合(ECMO)基础上加用连续性血液滤过可能会加速炎症介质清除并改善血流动力学稳定性,但相关证据仍然有限。我们分析了44例接受ECMO-血液滤过联合治疗的脓毒性休克患者(ECMO组),并将其与92例未接受ECMO或肾脏替代治疗的脓毒性休克患者(非ECMO组)进行比较。这项回顾性单中心研究纳入了2018年1月至2025年3月期间收治的成年患者。从电子记录中提取人口统计学、血流动力学、实验室检查及预后数据。主要结局为28天死亡率;次要结局包括重症监护病房(ICU)住院时间、无血管活性药物使用天数以及72小时序贯器官衰竭评估(SOFA)评分的变化。基线年龄(49.2±15.3岁对52.6±16.1岁;P=0.28)和急性生理与慢性健康状况评分系统II(APACHE II)(27.8±5.7对26.9±6.0;P=0.41)具有可比性。24小时时,ECMO组平均动脉压从52.3±7.4 mmHg升至67.8±9.1 mmHg(平均变化[∆]+15.5 mmHg,P<0.001)。对照组平均动脉压仅适度升高4.9 mmHg,未达到统计学显著性(P=0.07)。ECMO治疗后炎症标志物下降更为明显(白细胞介素-6[IL-6]∆-778 pg/mL对-248 pg/mL,P<0.001)。ECMO组SOFA评分下降3.6±2.2分,而对照组下降1.6±2.4分(P=0.01)。28天死亡率无差异(40.9%对48.9%,P=0.43),但ECMO组ICU住院时间更长(中位数12.5天对9.3天,P=0.002)。IL-6的变化与SOFA评分的变化相关(ρ=0.46,P=0.004)。ECMO辅助血液滤过改善了早期血流动力学和器官衰竭评分,并加速了细胞因子清除,尽管粗死亡率未变。需要开展更大规模的前瞻性试验来明确生存获益及最佳患者选择。